LONG TERM IMPACT OF RACE/ETHNICITY ON DEATH, MYOCARDIAL INFARCTION AND STROKE AMONG PATIENTS ENROLLED IN THE BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION OF TYPE 2 DIABETES TRIAL (BARI 2D)  by Beohar, Nirat et al.
A128.E1195
JACC March 9, 2010
Volume 55, issue 10A
 MYOCARDIAL ISCHEMIA AND INFARCTION 
LONG TERM IMPACT OF RACE/ETHNICITY ON DEATH, MYOCARDIAL INFARCTION AND STROKE AMONG 
PATIENTS ENROLLED IN THE BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION OF TYPE 2 
DIABETES TRIAL (BARI 2D)
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Stable Ischemic Syndrome--Clinical Drivers of Risk and Outcomes
Abstract Category: Stable Ischemic Syndrome
Presentation Number: 1269-315
Authors: Nirat Beohar, Veronica Sansing, V.S. Srinivas, Andrew Davis, Stephen Thomas, Tarek Helmy, Luis Lepe, Maria Brooks, BARI 2D Study Group, 
Northwestern University, Chicago, IL, University of Pittsburgh, Pittsburgh, PA
Background: To evaluate the impact of race/ethnicity on cardiovascular outcomes among patients with type 2 diabetes mellitus (DM) and 
coronary artery disease (CAD) in BARI 2D.
Methods: Patients from US and Canada (Total n= 1852, White n=1189, Black n=349, Hispanic n=212) were randomized to coronary 
revascularization and intensive medical therapy (IMT) vs IMT and insulin sensitization vs provision. Average follow-up was 5.3 yrs.
Results: Risk factors varied by race/ethnicity (White, Black, Hispanic) at baseline (p across groups): LDL ≥100 mg/dl, BP >130/80 mmHg, 
HbA1c≥7%, Albumin/creatinine ratio (ACR) > 300 (p<0.001) and BMI (p=0.01). Blacks had a significantly lower burden of CAD: Myocardial jeopardy: 
mean 44, 39, 40 (p=0.001).
At 5 year follow up, risk factor profiles were significantly better for all groups however differences persisted (all p=0.001). The use of aspirin, statins, 
ACE-I, TZDs, biguanide and sulfonyl ureas was similar except beta blockers (p=0.02) and insulin (p=0.005) across groups.
The adjusted 5 year outcomes did not vary significantly by race/ethnicity. (Table)
Conclusions: In BARI 2D, significant race/ethnic differences in baseline CAD and risk profile that persisted throughout follow up did not translate 
into significant differences in 5 year rates of Death or Death/MI/Stroke. Closely monitored IMT appears to mitigate the impact of differences in risk 
factors and burden of CAD by race/ethnicity on clinical outcomes.
Table: Adjusted hazard ratios by Race/Ethnicity
HAZARD RATIOS/Adjusted 95% CI p-value
DEATH
Black nH 1.24 0.52-1.58 0.23
Hispanic 0.86 0.36-1.36 0.57
White nH (reference) 1.00 0.79-1.31 0.73
DEATH/MI/STROKE
Black nH 1.05 0.79-1.31 0.73
Hispanic 0.82 0.46-1.18 0.28
White nH 1.00
